Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016

Bharatbook added a new report on "Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016" which gives comprehensive and effective methods to tackle atrial fibrillation.
Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 report ( http://www.bharatbook.com/detail.asp?id=132168&rt=Atrial-Fibrillation-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html ) is an essential source of information and analysis on the global atrial fibrillation market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atrial fibrillation sector.

The Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016
The atrial fibrillation (AF) market is currently on the brink of rapid expansion due to the expected launch of novel products between 2010 and 2016 with new first-in-class molecules likely to replace the age-old generics which have been dominating the market, chiefly due to their low costs and a lack of suitable alternatives. The latest entrant into the market was Multaq in 2009. It was launched after the loss of patent protection for Sanofi-Aventis's previous anti-arrythmic drug, Cordarone (amiodarone) in the US in 2002. The presently marketed products have numerous adverse events and associated toxic side-effects. It would, therefore, be sufficient for newer entrants to demonstrate a superior efficacy and safety profile in order to capture value in the market from the currently used generic drugs.

In-depth analysis reveals that Stedicor is likely to dominate the future AF market followed by Kynapid, given that there were numerous safety related concerns over Multaq in patients. Nevertheless, the market is all set to witness a definite paradigm shift in the treatment of atrial fibrillation with the entry of new products that would command higher prices owing to their clinical superiority. Increase in the treatment seeking population, prescription rates and an increase in the ageing global population are considered to be important drivers for this market. A high projected growth rate is primarily attributable to the potentially strong late stage pipeline. Availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the atrial fibrillation market.

Atrial Fibrillation Market Set to Witness A Race for the Next Blockbuster Product
The current competition in the atrial fibrillation market to be weak as the market is mainly governed by generics that have comparable safety and efficacy profiles. This apart, major revenue for this market are generated by anticoagulants, which are prescribed in addition to anti-arrythmics to achieve a superior rate of rhythm control in patients. The anticoagulants market is in itself set to witness a remarkable growth rate with the approval of newer oral anticoagulants. The entry of these newer classes of drugs will undoubtedly accelerate the growth of the atrial fibrillation market also and annul the use of warfarins and other vitamin K antagonists. This would, in turn, start a race among the new entrants to capture value in the market and kick-start a phase of unprecedented growth. Procter and Gamble’s (P & G’s) Stedicor is expected to lead sales in the atrial fibrillation market in the next few years. However, other products, such as Multaq, Pradaxa, and Xarelto are likely to give strong competition to Stedicor. The entry of newer atrial fibrillation agents would propel the growth of the market forward, with an estimated quadrupling of the current market revenues.

New Entrants Are likely to Bring A Paradigm Shift in Conventional treatment options for Atrial Fibrillation
The presently available treatment options are moderately successful in meeting the market demand. Newer anti-arrhythmic drugs, which block multiple channels or have specificity for the atrial myocardium, are believed to present a more favorable risk-benefit ratio than traditional anti-arrhythmic drugs. As a wider perspective is likely to develop in the future among physicians and cardiologists, due to the entry of novel drugs in the market, the genesis of a new and refined atrial fibrillation drug therapy is predicted to emerge, with gap junction modulators, ion channel blockers and effective oral anti-coagulation therapies leading the way. These may offer more comprehensive and effective methods to tackle atrial fibrillation. A paradigm shift is therefore predicted in this market.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132168&rt=Atrial-Fibrillation-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

Renewable Energy Government Incentive Programs

Bharatbook added a new report on "Renewable Energy Government Incentive Programs" which gives continued investment and growth in the renewable energy sector.
Renewable Energy Government Incentive Programs report ( http://www.bharatbook.com/detail.asp?id=132176&rt=Renewable-Energy-Government-Incentive-Programs.html ) examines the current federal and state renewable energy incentive programs designed to encourage continued investment and growth in the renewable energy sector. The report is organized by state.

Federal and state governments are offering a myriad of renewable energy incentive programs, devised to encourage industry growth and energy savings through government-funded consumer and commercial initiatives, including tax rebate programs, and grants.

In recent years, renewable energy has become an important part of the United States’ government’s agenda. For instance, the Federal Energy Policy Act of 2005 (EPACT) established a tax deduction for energy-efficient commercial buildings applicable to qualifying systems and buildings.

More recently, the American Recovery and Reinvestment Act of 2009 extended many tax incentives originally introduced in EPACT and amended in the Emergency Economic Stabilization Act of 2008.

In 2008, total renewable energy consumption in the U.S. was 7315711 billion Btu, an over 7.5% increase from the year before. Hydroelectric power accounted for 33.5 percent of total renewable energy consumption. And biomass accounted for 53.25 percent. The remaining consumption is split between wind (7%), geothermal (5%), and solar (1.25%).

According to the EIA, the outlook for the next two decades is for continued U.S. reliance on fossil fuels, with coal growing faster than liquid fuels and natural gas. Modest growth in hydroelectric power and nuclear electric power is anticipated, as is a doubling of nonhydroelectric renewable energy by 2030.


To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132176&rt=Renewable-Energy-Government-Incentive-Programs.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline

Bharatbook.com added a new report on "Whats Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline" which gives development in Vaccines market.
Whats Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline report ( http://www.bharatbook.com/detail.asp?id=131989&rt=Whats-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline.html ) examines and estimates the market for vaccines that have yet to be launched, including the following target areas : Addiction, Allergy, Alzheimer’s Disease, Anthrax, Asthma,Campylobacter Infection, Chlamydia, Croup, Dengue Fever, Diabetes, Ebola, Epstein-Barr Virus, Enterotoxigenic Escherichia coli,Helicobacter Pylori, Hepatitis, Herpesvirus, Hookworm, Hypertension, HIV/AIDS, Leishmaniasis, Malaria, MRSA Infection, Multiple Sclerosis, Obesity, Parainfluenza Virus Type 3, Parkinson’s Disease, Plague, Respiratory Syncytial Virus, Ross River Virus, Shigellosis, Smoking, Stroke,
Tuberculosis, West Nile Virus

The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market?

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

Acambis plc, ACE BioSciences, AFFiRiS, ALK-Abello A/S, Allergy Therapeutics, Bavarian Nordic A/S, Baxter Healthcare, Celldex Therapeutics, Crucell, Cytos Biotechnology Financial GlaxoSmithKline, Hawaii Biotech, Intercell, Medimmune, Merck & Co. Inc, Mymetics, Nabi Biopharmaceuticals, Novartis, Opexa Therapeutics, Paladin Labs, Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded an entire report on this topic. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=131989&rt=Whats-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

SCM Market in China 2008-2012

Bharatbook.com added a new report on "SCM Market in China 2008-2012" which gives the Global Cardiovascular Devices market and profiles the key vendors of this industry.
SCM Market in China 2008-2012 report ( http://www.bharatbook.com/detail.asp?id=129842&rt=SCM-Market-in-China-2008-2012.html ) assesses that the Supply Chain Management (SCM) includes tools that enable efficient management of processes; concerned with planning, implementing and controlling the supply chain operations. Logistic applications, production planning tools, and inventory management tools are some of the tools used in SCM.

In the face of the current uncertainty in the global economy, there has been an increase in the usage of SCM tools for the delivery of effective supply chain. The companies are looking to optimize flows within the organizations by getting an end-to-end view of the supply chain process and accurate information. Over the years, SCM solutions have evolved to provide information for the seamless integration of strategic options and tactical operational planning.

The Chinese economy is witnessing an increasing growth rate from last few decades. These developments are offering a huge potential to the multinational companies, which are looking for the expansion of their business operations in China. The increase of global operations and the need for improved effectiveness of production is leading to the upgradation of the IT systems, including SCM in China.

The report forecasts the market size of the SCM market in China for 2008-2012. It also discusses the market trends, drivers and challenges of the SCM in the Chinese market, and also profiles the key vendors in this industry.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=129842&rt=SCM-Market-in-China-2008-2012.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

Drug Discovery In India and China - Gaining Momentum with Increasing Pressure on Cost Cutting

Drug Discovery In India and China - Gaining Momentum with Increasing Pressure on Cost Cutting report ( http://www.bharatbook.com/detail.asp?id=130313&rt=Drug-Discovery-in-India-and-China-Gaining-Momentum-with-Increasing-Pressure-on-Cost-Cutting.html ) provides key data, information and analysis of the major trends and issues affecting the Drug Discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the key services that form a part of drug discovery process. The report also provides a detailed analysis Indian and Chinese drug market in terms of its size, share in the global drug discovery market, major service offering of the companies in India and China along with the major therapeutic areas of focus under those services. The report also talks about the factors that are driving the drug discovery market in India and China. The report delves into the key regulations, especially with respect to intellectual property rights protection in the two countries and how the regulations have benefited the drug discovery companies in these two nations. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. The report also analyses key partnerships between the western pharma and the local companies in the two countries and the key trends emerging out of such partnerships. At the end, the report looks into the major challenges in the future that can restrict the growth of the drug discovery market in India and China.

Rising Financial and Regulatory Pressures on Western Pharma will Continue to Drive the Drug Discovery Research Market Growth in India and China
The pharmaceutical industries in the US and Europe are facing severe financial constraints which are expected to worsen in the years ahead. The pharma companies are under increasing pressure to reduce expenditure due to, the increasing cost of introducing a NME (New Molecular Entities) (more than $3 billion in 2008), tightening FDA regulatory issues, blockbuster drugs worth more than $100 billion set to expire by 2014 and drying pipelines These pressures are expected to drive the companies towards low-cost countries such as India and China to perform their R&D activities, one of their major expenses.
Over the last decade, India and China have developed significant capabilities in drug discovery research along with considerable capabilities in phase I & II clinical trials. Both countries are able to provide significant cost savings in the range of 60–70% for discovery research and clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the Western pharmaceutical industry, outsourcing to low-cost countries is logical.

Inflammatory Diseases, Metabolic Disorders and Oncology are the Three Major Therapeutic Areas of Drug Discovery Research in India and China
While the Indian and Chinese drug discovery companies have developed major service capabilities, many of the companies have also defined their therapeutic research focus. Analysis of 12 Indian and 10 Chinese companies research portfolios reveal that inflammatory diseases (18 companies), metabolic disorders (18) and cancer (16) are the top three therapeutic areas Other major therapy areas include anti-infectives and CNS (Central Nervous System). Major inflammatory disease research includes; COPD (- Chronic Obstructive Pulmonary Disease), RA (Rheumatoid Arthritis), psoriasis, osteoarthritis, ulcerative colitis and atherosclerosis.
However, at the country level the therapeutic focus is found to be different. Indian companies have concentrated their efforts on metabolic disorders; primarily diabetes, obesity and dyslipidemia. Chinese companies have focused on oncology; primarily leukemia, cervical cancer, breast cancer and prostrate cancer.

Deals Landscape is Equally Driven by Mid-Size Pharma and Big Pharma with Oncology and Metabolic Disorders as Key Therapy Area of Focus
With improvements in the capabilities of Indian and Chinese companies, the intensity of discovery research collaborations with Western pharmaceutical companies has increased.. The deals market has been equally driven by big pharma as well as mid-size pharma. Over the past year, 41 major deals have taken place in India and China, of which 20 deals involved mid-size companies while 19 involved big pharma; mainly Merck, AstraZeneca, Johnson & Johnson and Pfizer. Two of the deals were with universities. However, the increasing interest of the mid-size pharmaceutical companies suggests the rising interest of such companies to exploit the cost and quality capabilities of India and China.

Many of these deals were focused on services rather than a therapeutic area. However, among those that had a therapeutic focus; oncology, metabolic disorders, infectious diseases and inflammatory diseases were the major therapies targeted.

Funding Problems and Talent Shortage Will Be the Two Biggest Challenges in Future for the Drug Discovery Players in India and China
While the drug discovery market in India and China is growing rapidly, its future growth faces two major challenges; funding problems, especially for the private companies, and significant talent shortages in biology and chemistry services. While China has considerable government support, a large part of the money goes to government funded research institutions and universities. In India, the government has adopted PPP model as a tool to encourage pharmaceutical innovation but the major beneficiaries include CSIR (Council of Scientific and Industrial Research) affiliated institutes and small pharmaceutical companies. Venture capitalists, in both the countries, are largely risk-averse to invest in early stage R&D activities.
Besides funding problems, the lack of a sufficient talent pool with the specialized skills, experience and employability will create further problems for the drug discovery companies in both the countries.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=130313&rt=Drug-Discovery-in-India-and-China-Gaining-Momentum-with-Increasing-Pressure-on-Cost-Cutting.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

Mobile Applications - Impacts on Network Operations and Wireless Business Opportunities

Bharatbook added a new report on "Mobile Applications: Impacts on Network Operations and Wireless Business Opportunities" which gives the In-depth analysis on Mobile applications.

Mobile Applications Impacts on Network Operations and Wireless Business Opportunities report ( http://www.bharatbook.com/detail.asp?id=130297&rt=Mobile-Applications-Impacts-on-Network-Operations-and-Wireless-Business-Opportunities.html ) focuses on the smart phone's mobile applications impact in the wireless marketplace, especially with respect to network operations and business opportunities. Due to the rapid growth and evolution of the smart phone market, there are many conflicting developments now occurring. There are over 130 smart phone models currently on the market. The marketplace has developed quickly and there are only a few models that are popular and we will focus only on these units. This publication evaluates these particular smart phones and their impact on the wireless marketplace.

Key Findings:

* The Mobile application market forecast is a $9.0 billion revenue opportunity over the next few years.
* As the network operators desired, customers acquired smartphones and wireless data applications to improve their productivity.
* Due to the popularity of the Apple iPhone, the network operators supporting the iPhone are experiencing traffic congestion and throughput problems in areas with high concentrations of iPhone users.
* The handset vendors have taken the leadership role away from the network operators and are currently driving this market.
* Apple has defined and driven this market to its current state. All other players in this market are reacting to Apple and playing catch up.
* Statistics show smart phones generate 30 times the traffic of basic cell phones leading to the network congestion being experienced.

Questions Answered

* What is behind the network congestion on ATT network?
* Why did this happen?
* Can it be corrected?
* Where will this market go?

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=130297&rt=Mobile-Applications-Impacts-on-Network-Operations-and-Wireless-Business-Opportunities.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

Stem Cell Research - An integral part of therapeutics

Bharatbook added a new report on "Stem Cell Research – Market Trends, Investment Trends and Pipeline Analysis" which gives the key geographies and the role of Stem Cell Research.

Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis report ( http://www.bharatbook.com/detail.asp?id=130308&rt=Stem-Cell-Research-Market-Trends-Investment-Trends-and-Pipeline-Analysis.html ) revealed that High Unmet Needs Associated with Chronic Diseases Boosts Stem Cell Research and Development. Stem cell therapies are expected to serve the unmet needs that are associated with treatment of certain chronic diseases. In spite of advancements in medical technology, there are very few treatment options available in the market to cure certain cardiovascular disorders, cancers, autoimmune and inflammatory disorders, spinal cord injury and others. Also, most of these therapies treat the symptoms without curing the disease. Stem cell therapies have the capacity to fill this gap of unmet need through its novel therapeutic approach that has the ability to cure the diseases.

High Market Potential for Stem Cell Therapies has resulted in Establishing Strategic Partnerships between Large Pharmaceutical Companies and Stem Cell Research Based Companies
Strategic partnerships between Pharmaceutical companies and Stem cell research companies have given a boost to stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence, all major pharmaceutical companies look forward to new technologies that would increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next five years. Pharmaceutical companies are also keen to explore various methods where stem cells could be utilized in the drug discovery process that would accelerate the discovery of novel drug molecules.

Promising Pipeline in Phase II and Phase III has Increased the Hopes of Commercialization of Stem Cell Therapies
The total number of stem cell clinical trials has increased tremendously over the last few years. The number of Phase II clinical trials has witnessed more than a 40% jump between 2005 and 2008. With more than five ongoing Phase III trials, the market is keenly awaiting the launch of these therapies within the next five years. The Preclinical research and Phase I trials have also increased at a phenomenal rate. This increase demonstrates the emerging interests in stem cell research across the globe.

Supportive Regulatory Environment Coupled with Increase in Investments have Bolstered the Growth of Stem Cell Research
In the United States, President Barack Obama has lifted the federal funding restrictions on embryonic stem cell research. With the removal of this barrier, the authority of the department of health and human services, including the National Institutes of Health (NIH) will encourage support for human embryonic stem cell research. This will enable new therapies and new discoveries and will potentially lead to dramatic advances in the understanding and treatment of conditions such as diabetes, heart diseases and Alzheimer’s. The federal funding and VC funding for stem cell research is also expected to increase with this amendment from the US government.

Key Geographies are Attracting Investments by Promoting Stem Cell Tourism
Countries that are advanced in providing stem cell therapies are taking advantage to attract investments from other countries by promoting stem cell tourism. The lack of stem cell therapy in a country forces the citizens suffering from debilitating conditions to travel to other countries where stem cell treatment is available. There has been an increase in the number of patients traveling from developed nations to countries like China, Thailand, Germany, Dominican Republic, Costa Rica, Israel and Argentina. Most of these countries promote stem cell tourism. This has the potential for excellent revenue generation for these countries.

The role of stem cell research as an integral part of therapeutics, as well as its commercial potential is now being recognized by most major countries of the world. Stem cell based therapies have immense market potential, driven by a strong pipeline that caters to high unmet needs. Stem cell research is now firmly on the path to being developed and commercialized fully. Currently, the technology is in its early stages of development, which implies that barriers to entry in this market are relatively low. Meeting the vast unmet need that stem cell research will eventually target, along with a strong pipeline of therapeutic candidates, suggests that it is a fast growing market that will offer attractive opportunities for investment in the near future.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=130308&rt=Stem-Cell-Research-Market-Trends-Investment-Trends-and-Pipeline-Analysis.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook